Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

759316

544578

RUBICON

img img img img
No Data Available

Rubicon Research Ltd performance

Today’s low

Today’s high

₹ 666.55 ₹ 684.95
₹ 675.65

52 week low

52 week high

₹ 570.75 ₹ 754.80
₹ 675.65

Open Price

₹ 672.60

Prev. Close

₹ 681.25

Volume (Shares)

185922.00

Total traded value

₹ 1256.18

Upper Circuit

₹ 817.50

Lower Circuit

₹ 545.00

info

Rubicon Research Ltd Share Price Update

As of the latest trading session, Rubicon Research Ltd share price is currently at ₹ 675.65, which is down by ₹ -5.59 from its previous closing. Today, the stock has fluctuated between ₹ 666.55 and ₹ 684.95. Over the past year, Rubicon Research Ltd has achieved a return of [-] %. In the last month alone, the return has been 5.26 %. Read More...

Investment Returns

Over 1 Month [-]% Over 3 Months [-]% Over 6 Months 0.00% Over 1 Year 0.00%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

Rubicon Research Ltd fundamentals


  • Market cap (Cr)

    11,131.40

  • P/E Ratio (TTM)

    66.75

  • Beta

    1.13

  • Book Value / share

    71.10

  • Return on equity

    29.30%

  • EPS (TTM)

    10.22

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    45.81

info icon alternate text
  • Market cap (Cr)

    11,183.30

  • P/E Ratio (TTM)

    66.75

  • Beta

    0.86

  • Book Value / share

    71.10

  • Return on equity

    29.30%

  • EPS (TTM)

    10.22

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    45.81

info icon alternate text

Rubicon Research Ltd Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars SEP 2025 (Values in Cr)
Revenue 336.47
Operating Expense 276.34
Net Profit 45.81
Net Profit Margin (%) 13.61
Earnings Per Share (EPS) 2.97
EBITDA 80.62
Effective Tax Rate (%) 25.66
Particulars JUN 2025 (Values in Cr)
Revenue 278.03
Operating Expense 232.03
Net Profit 35.15
Net Profit Margin (%) 12.64
Earnings Per Share (EPS) 2.28
EBITDA 64.59
Effective Tax Rate (%) 25.88
Particulars SEP 2024 (Values in Cr)
Revenue 254.90
Operating Expense 200.19
Net Profit 42.89
Net Profit Margin (%) 16.82
Earnings Per Share (EPS) 2.82
EBITDA 71.23
Effective Tax Rate (%) 25.46
Particulars JUN 2024 (Values in Cr)
Revenue 273.27
Operating Expense 0.00
Net Profit 46.16
Net Profit Margin (%) 16.89
Earnings Per Share (EPS) 2.99
EBITDA 0.00
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 1073.84
Operating Expense 870.25
Net Profit 167.54
Net Profit Margin (%) 15.60
Earnings Per Share (EPS) 11.00
EBITDA 289.58
Effective Tax Rate (%) 24.96
Particulars MAR 2025 (Values in Cr)
Book Value / Share 35.10
ROE % 29.02
ROCE % 25.02
Total Debt to Total Equity 0.91
EBITDA Margin 20.86
Particulars MAR 2024 (Values in Cr)
Book Value / Share 25.31
ROE % 27.11
ROCE % 18.42
Total Debt to Total Equity 1.11
EBITDA Margin 20.27
Particulars MAR 2023 (Values in Cr)
Book Value / Share 564.84
ROE % -5.71
ROCE % 1.45
Total Debt to Total Equity 0.84
EBITDA Margin 11.17
Particulars MAR 2022 (Values in Cr)
Book Value / Share 602.36
ROE % -19.75
ROCE % -11.80
Total Debt to Total Equity 0.39
EBITDA Margin -7.14
Particulars MAR 2021 (Values in Cr)
Book Value / Share 737.96
ROE % 8.59
ROCE % 17.01
Total Debt to Total Equity 0.17
EBITDA Margin 32.35
Particulars MAR 2025 (Values in Cr)
Book Value / Share 43.33
ROE % 29.30
ROCE % 26.05
Total Debt to Total Equity 0.72
EBITDA Margin 26.97
Particulars MAR 2024 (Values in Cr)
Book Value / Share 31.29
ROE % 6.39
ROCE % 8.61
Total Debt to Total Equity 0.96
EBITDA Margin 15.79
Particulars MAR 2023 (Values in Cr)
Book Value / Share 564.84
ROE % -4.72
ROCE % 1.31
Total Debt to Total Equity 0.68
EBITDA Margin 11.17
Particulars MAR 2022 (Values in Cr)
Book Value / Share 845.39
ROE % 3.97
ROCE % 4.68
Total Debt to Total Equity 0.31
EBITDA Margin 14.36
Particulars MAR 2021 (Values in Cr)
Book Value / Share 811.56
ROE % 13.81
ROCE % 21.00
Total Debt to Total Equity 0.16
EBITDA Margin 36.86
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 116.23
Total Assets 1451.43
Total Liabilities 1451.43
Total Equity 540.98
Share Outstanding 154126676
Price to Book Ratio 0.00
Return on Assets (%) 9.25
Return on Capital (%) 14.38
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 58.39
Total Assets 1109.48
Total Liabilities 1109.48
Total Equity 385.00
Share Outstanding 152099340
Price to Book Ratio 0.00
Return on Assets (%) 8.20
Return on Capital (%) 11.65
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 58.91
Total Assets 749.70
Total Liabilities 749.70
Total Equity 286.37
Share Outstanding 5069978
Price to Book Ratio 0.00
Return on Assets (%) -2.25
Return on Capital (%) -2.79
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 52.60
Total Assets 559.51
Total Liabilities 559.51
Total Equity 305.39
Share Outstanding 5069978
Price to Book Ratio 0.00
Return on Assets (%) -11.99
Return on Capital (%) -14.13
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 85.98
Total Assets 538.25
Total Liabilities 538.25
Total Equity 374.14
Share Outstanding 5069978
Price to Book Ratio 0.00
Return on Assets (%) 5.70
Return on Capital (%) 6.73
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 37.10
Total Assets 1340.93
Total Liabilities 1340.93
Total Equity 667.78
Share Outstanding 154126676
Price to Book Ratio 0.00
Return on Assets (%) 12.49
Return on Capital (%) 15.79
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 48.25
Total Assets 1016.59
Total Liabilities 1016.59
Total Equity 475.86
Share Outstanding 152099340
Price to Book Ratio 0.00
Return on Assets (%) 2.39
Return on Capital (%) 2.79
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 58.91
Total Assets 749.70
Total Liabilities 749.70
Total Equity 286.37
Share Outstanding 5069978
Price to Book Ratio 0.00
Return on Assets (%) -2.25
Return on Capital (%) -2.79
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 43.50
Total Assets 678.33
Total Liabilities 678.33
Total Equity 428.61
Share Outstanding 5069978
Price to Book Ratio 0.00
Return on Assets (%) 2.45
Return on Capital (%) 2.79
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 78.64
Total Assets 569.59
Total Liabilities 569.59
Total Equity 411.46
Share Outstanding 5069978
Price to Book Ratio 0.00
Return on Assets (%) 9.29
Return on Capital (%) 10.5
Particulars MAR 2025 (Values in Cr)
Net Income 194.52
Cash from Operations 197.92
Cash from Investing -64.80
Cash from Financing -39.81
Net change in Cash 54.55
Free Cash Flow 268.15
Particulars MAR 2024 (Values in Cr)
Net Income 102.85
Cash from Operations 39.08
Cash from Investing -68.51
Cash from Financing 43.55
Net change in Cash -3.95
Free Cash Flow 95.22
Particulars MAR 2023 (Values in Cr)
Net Income -11.04
Cash from Operations -72.92
Cash from Investing -33.82
Cash from Financing 122.81
Net change in Cash 14.24
Free Cash Flow -28.46
Particulars MAR 2022 (Values in Cr)
Net Income -66.11
Cash from Operations -54.16
Cash from Investing -54.92
Cash from Financing 63.05
Net change in Cash -54.50
Free Cash Flow 0.33
Particulars MAR 2021 (Values in Cr)
Net Income 63.12
Cash from Operations 95.11
Cash from Investing -46.09
Cash from Financing 51.50
Net change in Cash 67.08
Free Cash Flow 166.39
Particulars MAR 2025 (Values in Cr)
Net Income 223.27
Cash from Operations 56.50
Cash from Investing -10.03
Cash from Financing -34.04
Net change in Cash -14.43
Free Cash Flow 126.97
Particulars MAR 2024 (Values in Cr)
Net Income 34.07
Cash from Operations 99.08
Cash from Investing -130.48
Cash from Financing 45.86
Net change in Cash -1.42
Free Cash Flow 155.00
Particulars MAR 2023 (Values in Cr)
Net Income -11.04
Cash from Operations -72.92
Cash from Investing -33.82
Cash from Financing 122.81
Net change in Cash 14.24
Free Cash Flow -28.46
Particulars MAR 2022 (Values in Cr)
Net Income 16.92
Cash from Operations -61.51
Cash from Investing -52.21
Cash from Financing 65.22
Net change in Cash -49.07
Free Cash Flow -61.51
Particulars MAR 2021 (Values in Cr)
Net Income 85.38
Cash from Operations 81.14
Cash from Investing -31.63
Cash from Financing 52.17
Net change in Cash 70.14
Free Cash Flow 81.14
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 26.51 13.00 1.37 203.15 25.97 / 53.83
BLISS GVS PHARMA LTD 172.15 16.62 1.60 1821.16 105.05 / 195.85
CIPLA LTD 1397.95 20.75 3.43 112922.38 1310.05 / 1672.20
FERMENTA BIOTECH LIMITED 333.20 8.75 2.50 980.64 219.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 26.51 21.55 3.69 203.15 25.97 / 53.83
AMRUTAJAN HEALTH LTD 610.00 31.11 5.15 1763.55 548.05 / 789.95
ASTRAZENECA PHARMA IND LT 8251.95 89.24 25.81 20629.88 6501.60 / 10653.05
BLISS GVS PHARMA LTD 172.15 23.23 1.65 1821.16 105.05 / 195.85

Rubicon Research Ltd shareholding pattern

Holding

20.09%
59.98%
9.37%
10.54%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

Rubicon Research Ltd Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
675.65 -0.82 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 675.10
  • 26 Days 665.20
  • 10 Days 673.00
  • 50 Days 655.80
  • 12 Days 672.10
  • 100 Days 650.30
  • 20 Days 668.30
  • 200 Days 650.30
675.52 PIVOT

First Support

665.63

First Resistance

691.13

Second Support

650.02

Second Resistance

701.02

Third Support

640.13

Third Resistance

716.63

RSI

53.28

ADX

16.90

MACD

6.91

Williams % R

-29.70

Commodity Channel Index (CCI)

37.91

Date

2026-01-16

Week

108970.00

Same Day

132410.00

Month

90061.00

1 Year

1.13

3 Year

1.12

Over 1 Month

5.26%

down

Over 1 Year

0.00%

down

Over 3 Months

7.55%

down

Over 3 Years

0.00%

down

Over 6 Months

0.00%

down

Over 5 Years

0.00%

down

Rubicon Research Ltd Corporate Actions

Top Gainers

Rubicon Research Ltd Share Price

Rubicon Research Limited was incorporated on May 6, 1999, as a Private Company as Rubicon Consultants Private Limited', with the RoC. Subsequently, the Company's name was changed from Rubicon Consultants Private Limited' to Rubicon Research Private Limited' to which a fresh Certificate of Incorporation was issued by the RoC dated September 2, 2002. The Company's status got converted from a Private Company to a Public Company, the name was changed from Rubicon Research Private Limited' to Rubicon Research Limited'. A fresh Certificate of Incorporation dated July 23, 2024 was issued by the Central Processing Centre, Manesar, Haryana.

Rubicon Research is an integrated pharmaceutical company with business encompassing the entire value chain in the research, development and production of pharmaceutical products. The Company is driven by innovation through focused research and development, with an increasing portfolio of specialty products and drug-device combination products targeting regulated markets, particularly, the United States. It has obtained its GMP manufacturing facilities at Ambernath and Satara in Maharashtra.

The Company commenced manufacturing of certain special drugs in Ambernath Manufacturing Facility in 2011. In 2016, the Company acquired majority stake by ECP III Pte Ltd. Further, it acquired majority stake by General Atlantic Singapore RR Pte. Ltd., from ECP III Pte. Ltd. in 2019. In 2021, the Company acquired the business of Meditab Specialities Limited on slump sale as a going concern.

In FY 2024, the Company acquired Validus, a New Jersey headquartered marketer of brand name formulation products in the US. It commenced the manufacturing of nasal products at Ambernath Plant in 2024. The Company has acquired Pithampur Manufacturing Facility from Alkem Laboratories Ltd in 2025.

The Company came up with its initial public offering of 28,405,841 equity shares of face value of Re 1 each, by raising funds aggregating to Rs 1378 crores, comprising a fresh issue of 10,313,058 equity shares aggregating to Rs 500 crores and the offer for sale of 18,092,783 equity shares aggregating to Rs 878 crores on October 13, 2025.

Parent organization Indian Private
NSE symbol RUBICON
Founded 1999
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Rubicon Research Ltd?

Answer Field

Rubicon Research Ltd share price is for NSE ₹ 675.65 & for BSE ₹ 675.10 as on Jan 16 2026 03:30 PM.

What is the Market Cap of Rubicon Research Ltd Share?

Answer Field

The market cap of Rubicon Research Ltd for NSE ₹ 10,413.57 & for BSE ₹ 10,405.09 as on Jan 16 2026 03:30 PM.

What is the 52 Week High and Low of Rubicon Research Ltd?

Answer Field

The 52 Week High and Low of Rubicon Research Ltd for NSE is ₹ 754.80 and ₹ 570.75 and for BSE is ₹ 887.95 and ₹ 571.00.

What is 1 year return for Rubicon Research Ltd?

Answer Field

The 1 year returns on the stock has been 0.00%.

What is the P/E Ratio of Rubicon Research Ltd Share?

Answer Field

As on Jan 16 2026 03:30 PM the price-to-earnings (PE) ratio for Rubicon Research Ltd share is 66.75.

What is the PB ratio of Rubicon Research Ltd Share?

Answer Field

As on Jan 16 2026 03:30 PM, the price-to-book (PB) ratio for Rubicon Research Ltd share is 71.10.

How to Buy Rubicon Research Ltd Share?

Answer Field

You can trade in Rubicon Research Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Rubicon Research Ltd Share on Bajaj Broking App?

Answer Field

To buy Rubicon Research Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Rubicon Research Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59